Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Massachusetts General Hospital
Masonic Cancer Center, University of Minnesota
University of Chicago
Genmab
Fred Hutchinson Cancer Center
Mayo Clinic
UNC Lineberger Comprehensive Cancer Center
University of California, San Francisco
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
Gilead Sciences
The Lymphoma Academic Research Organisation
Sana Biotechnology
University of Arizona
Case Comprehensive Cancer Center
Celgene
City of Hope Medical Center
Sana Biotechnology
University of Maryland, Baltimore
National Taiwan University Hospital
Universität des Saarlandes
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Adicet Therapeutics
The First Affiliated Hospital of Nanchang University
Peking University Cancer Hospital & Institute
City of Hope Medical Center
Janssen Research & Development, LLC
Fred Hutchinson Cancer Center
MEI Pharma, Inc.
City of Hope Medical Center
University of Nebraska
Masonic Cancer Center, University of Minnesota
University of Nebraska
Fate Therapeutics
Henan Cancer Hospital
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Thomas Jefferson University
Roswell Park Cancer Institute
Universität des Saarlandes
Universität des Saarlandes
Masonic Cancer Center, University of Minnesota
National Taiwan University Hospital
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center